Previous 10 | Next 10 |
Innoviva (NASDAQ:INVA) priced its upsized offering of $225M principal amount of the 2.125% convertible senior notes due 2028; size of offering was increased from earlier announced $200M. Initial purchasers to be granted 13-days option to purchase up to an additional $45M principal amount...
Proceeds expected to be used to repurchase a portion of the 2023 Notes, fund capped call transactions, and for general corporate purposes Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million a...
Innoviva (NASDAQ:INVA) trades 6.7% down premarket after it plans to offer $200M in principal amount of convertible senior notes due 2028 in a private offering to qualified institutional buyers. Initial purchasers to be granted 13-days option to purchase up to an additional $40M...
Proceeds expected to be used to repurchase a portion of the 2023 Notes, fund capped call transactions, and for general corporate purposes Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced its intention to offer, subject t...
I think Innoviva's recent financial results have been quite good in many ways. Both revenue and net income are materially higher than both 2020 and 2019. I think Innoviva management likely overpaid for the stock buyback, but this isn't the worst thing in the world, in my view. The wor...
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
Innoviva Inc. (NASDAQ:INVA) traded today at a new 52-week high of $20.11. This new high was reached on below average trading volume as 135,000 shares traded hands, while the average 30-day volume is approximately 856,000 shares. Over the past year, Innoviva Inc. has traded in a range of ...
Gainers: Dermata Therapeutics (NASDAQ:DRMA) +35%. Innoviva (NASDAQ:INVA) +11%. Mainz Biomed (NASDAQ:MYNZ) +9%. Regional Health Properties (NYSE:RHE) +9%. Envista Holdings (NYSE:NVST) +8%. Losers: InfuSystem Holdings (NYSE:INFU) -22%. Sea...
Innoviva press release (NASDAQ:INVA): Q4 GAAP EPS of $0.14. Revenue of $107.68M (+19.0% Y/Y). Q4 net sales of RELVAR®/BREO® ELLIPTA® by GSK were $384.4M, up 3% Y/Y, with $158.2M in net sales from the U.S. market and $226.2M from non-U.S. markets. For further details see:...
Royalties increased by 18% to $111.1 million in the fourth quarter of 2021, compared to the same quarter in 2020; royalties increased by 19% to $405.7 million in full year 2021, compared to the prior year. Announced strategic investment of $45.0 million into Armata Pharmaceuti...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...